Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs
- 12 February 2008
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 28 (5), 773-796
- https://doi.org/10.1002/med.20119
Abstract
The renewed interest in glycogen synthase kinase‐3 (GSK‐3), involved in the molecular pathogenesis of human severe diseases, is focused on the potential of its inhibitors to treat diseases that have significant limitations in their current treatments. During the last 5 years, a lot of literature discuss progress in the search and pharmacological actions of GSK‐3 inhibitors, but now, evidence have been accumulated showing preclinical efficacy for these new drugs, in very different models of several distinct pathologies. These studies have been summarized in the present review offering promising examples for new therapies for diabetes, cancer, inflammation, Alzheimer's disease and other neurological pathologies, and mood disorders. Now, clinical human trials are awaiting to confirm the ray of hope that GSK‐3 inhibitors are arising for the future treatment of severe unmet diseases. © 2008 Wiley Periodicals, Inc. Med Res Rev, 28, No. 5, 773–796, 2008Keywords
This publication has 136 references indexed in Scilit:
- Lithium Reduces Tau Phosphorylation but Not Aβ or Working Memory Deficits in a Transgenic Model with Both Plaques and TanglesThe American Journal of Pathology, 2007
- The leukemic stem cellBest Practice & Research Clinical Haematology, 2007
- Regulation of Glycogen Synthase Kinase-3 in Patients with Affective DisordersBiological Psychiatry, 2007
- GSK-3 is a viable potential target for therapeutic intervention in bipolar disorderNeuroscience & Biobehavioral Reviews, 2007
- Inhibition of glycogen synthase kinase‐3β attenuates the development of carrageenan‐induced lung injury in miceBritish Journal of Pharmacology, 2006
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006
- The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathwaysProgress in Neurobiology, 2006
- Lithium Regulates Glycogen Synthase Kinase-3β in Human Peripheral Blood Mononuclear Cells: Implication in the Treatment of Bipolar DisorderBiological Psychiatry, 2006
- Crossregulation of NF‐κB by the APC/GSK‐3β/β‐catenin pathwayMolecular Carcinogenesis, 2004
- Glycogen synthase kinase-3β-mediated tau phosphorylation in cultured cell linesNeuroReport, 2003